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omalizumab 300 mg in patients with CIU/CSU regardless of the background therapy for urticaria. The safety proﬁle was
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744 CASALE ETALAbbreviations used
AE- Adverse event
CI- Conﬁdence intervalCIU- Chronic idiopathic urticaria
CSU- Chronic spontaneous urticaria
CU- Chronic urticariaDLQI- Dermatology Life Quality Index
HR- Hazard ratioHRQoL- Health-related quality of life
IgE- Immunoglobulin E




SAE- Serious adverse event
SC- SubcutaneousUAS- Urticaria activity score
UAS7- Urticaria activity score over 7 daysother endpoints were also evaluated. Safety data were pooled
from all 3 studies.
RESULTS: Mean ISS was signiﬁcantly reduced from baseline at
week 12 in the pooled ASTERIA I and II omalizumab 150- and
300-mg treatment arms and in the GLACIAL omalizumab 300-
mg arm. The weekly ISS reduction magnitude at week 12 was
similar between the omalizumab 300-mg groups in the
ASTERIA I and II pooled and GLACIAL studies. Similar treat-
ment effect sizes were observed across multiple endpoints.
Omalizumab was well tolerated and the adverse-event proﬁle was
similar regardless of background therapy for CIU/CSU. The
overall safety proﬁle was generally consistent with omalizumab
therapy in allergic asthma.
CONCLUSION: Omalizumab 300 mg was safe and effective in
reducing CIU/CSU symptoms regardless of background
therapy.  2015 The Authors. Published by Elsevier Inc. on
behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/). (J Allergy Clin Immunol Pract 2015;3:743-50)
Key words: Omalizumab; Urticaria; Chronic spontaneous;
Chronic idiopathic; Itch; Hive; Pruritus; Wheal; Antihistamine
Chronic idiopathic urticaria (CIU), also known as chronic
spontaneous urticaria (CSU), is deﬁned as wheals or angioedema
that occurs together or separately on an intermittent or constant
basis for at least 6 weeks with no apparent speciﬁc trigger.1
Second-generation H1-antihistamines are an effective ﬁrst-line
treatment in some patients with CIU/CSU.1 An increase in H1-
antihistamine dose up to 4-fold is considered second-line therapy.
However, some patients with severe CIU/CSU continue to
experience symptoms despite treatment with increased doses of
H1-antihistamines.
2-4 Third-line treatment options for patients
who do not achieve complete control of their symptoms with
increased dosages of H1-antihistamines have included short-term
corticosteriods, add-on therapy with cyclosporine, a leukotriene
receptor antagonist (LTRA), or omalizumab.1,5,6
Omalizumab is a humanized monoclonal antibody to
immunoglobulin E (IgE) that has been licensed for the treatment
of moderate to severe allergic asthma in the United States since2003 and for severe allergic asthma in Europe since 2005.7,8
It was recently approved for the treatment of CIU/CSU in
Europe and the United States.7,8 Omalizumab was studied in 3
phase III, randomized, double-blind, placebo-controlled, clinical
trials in patients with CIU/CSU. ASTERIA I9 and ASTERIA
II10 evaluated the efﬁcacy and safety of subcutaneous (SC)
omalizumab 75 mg, 150 mg, and 300 mg every 4 weeks versus
placebo in patients with CIU/CSU who remained symptomatic
despite treatment with approved dosages of second-generation
H1-antihistamines. GLACIAL
11 evaluated the safety and efﬁ-
cacy of omalizumab 300 mg SC every 4 weeks versus placebo in
patients who remained symptomatic despite treatment with up
to 4 times the approved dose of second-generation H1-antihis-
tamines and add-on H2-antagonists and/or LTRAs.
The data from the phase III clinical program represent the
largest database of patients reported to date with refractory CIU/
CSU with nearly 1000 patients included (omalizumab, n ¼ 733;
placebo, n ¼ 242). Guideline recommendations for the use of
omalizumab cite a strong, high level of evidence to support its use
in CIU/CSU.1 In this post hoc analysis, we compared the efﬁcacy
of omalizumab from the ASTERIA studies, which included only
approved doses of H1-antihistamines as background therapy, with
the efﬁcacy of omalizumab from the GLACIAL study, which
permitted higher doses of antihistamines as well as other types of
background therapy. An evaluation of the pooled safety data and
time to loss of response are also included.METHODS
Study design
ASTERIA I and ASTERIA II were multicenter, randomized,
double-blind, placebo-controlled studies of omalizumab 75 mg
(ASTERIA I, n ¼ 77; ASTERIA II, n ¼ 82), 150 mg (ASTERIA I,
n ¼ 80; ASTERIA II, n ¼ 82), or 300 mg (ASTERIA I, n ¼ 81;
ASTERIA II, n ¼ 79) versus placebo (ASTERIA I, n ¼ 80;
ASTERIA II, n ¼ 79) administered SC every 4 weeks in patients
who remained symptomatic despite treatment with approved doses
of H1-antihistamines. These studies were similar in design except for
the duration of treatment, which was 24 weeks and 12 weeks,
respectively (Figure 1). Observational follow-up continued in both
studies for 16 weeks after the last dose of omalizumab. The primary
efﬁcacy endpoint in both studies was change from baseline to week
12 in weekly itch severity score (ISS), a component of the urticaria
activity score over 7 days12 (UAS7, daily ISS intensity ratings range
from 0 [none] to 3 [intense and/or severe]; range 0-21). Both studies
included the following secondary endpoints evaluated at week 12:
change from baseline in UAS7, change from baseline in weekly
number of hives score, time to minimally important difference
(MID) response (5-point reduction) in weekly ISS, proportion of
patients with UAS7 6 (well-controlled symptoms), proportion of
patients who were weekly ISS MID responders, change from base-
line in weekly size of largest hive score, change from baseline in
overall Dermatology Life Quality Index (DLQI), proportion of
angioedema-free days from week 4 to week 12 of therapy, and
proportion of patients with UAS7 ¼ 0 (complete response). The
proportion of patients with complete response was an ad hoc analysis
for ASTERIA II. Time to loss of response (deﬁned as a loss of UAS7
6) was included as a prespeciﬁed exploratory endpoint in both
studies. GLACIAL was a 40-week (24 weeks of treatment and 16
weeks of observational follow-up), multicenter, randomized, double-
blind, placebo-controlled study of omalizumab 300 mg (n ¼ 252)
ASTERIA I 24-week treatment period Omalizumab 75, 150, 300 mg vs placebo 
16-week 
follow-up 
Efficacy endpoint, week 12 
Every 4 weeks injection 
GLACIAL
24-week treatment period 
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Approved doses of
H1-antihistamines
Up to 4X approved dose of
H1-antihistamine plus 
LTRA or H2-antihistamine, 
or all 3 in combination




FIGURE 1. Study designs. CIU, Chronic idiopathic urticaria; CSU, chronic spontaneous urticaria; LTRA, leukotriene receptor antagonist.
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symptomatic despite treatment with up to 4 times the approved
dosage of H1-antihistamines and either H2-antihistamines or
LTRAs, or all 3 in combination (Figure 1). The primary objective of
GLACIAL was to evaluate the safety of omalizumab versus placebo;
efﬁcacy was evaluated as a secondary objective. Secondary efﬁcacy
endpoints included the change from baseline in weekly ISS and the
other 9 endpoints listed above from ASTERIA I and II and were
evaluated at week 12. Time to loss of response was a prespeciﬁed
exploratory endpoint in GLACIAL. Diphenhydramine 25 mg was
allowed for itch relief in all 3 studies (up to a maximum of 3 doses or
less in 24 hours based on local regulations). All 3 studies were
conducted in accordance with US Food and Drug Administration
regulations, the International Conference on Harmonisation E6
Guideline for Good Clinical Practice, and any other applicable
country laws. Institutional review board approval and informed
consent was obtained from all research subjects. These trials are
registered with ClinicalTrials.gov, number NCT01287117
(ASTERIA I), number NCT01292473 (ASTERIA II), and number
NCT01264939 (GLACIAL).
Patients
Patients were eligible for inclusion in these studies if they met the
following criteria: age 12-75 years (18-75 years in Germany; per
German regulatory requirements), diagnosis of CIU/CSU for 6
months, presence of itch and hives for 8 consecutive weeks before
enrollment despite concurrent H1-antihistamine treatment at
approved doses (ASTERIA I and II) or presence of itch and hives for
>6 consecutive weeks before enrollment despite treatment with H1-
antihistamines at up to 4 times the approved dose plus LTRAs or
H2-antihistamines, or all 3 in combination (GLACIAL; baseline
medication use previously reported11), UAS7 16 (scale 0-42)
and weekly ISS 8 (scale 0-21) for the 7 days before randomization,in-clinic physician-assessed UAS 4 (scale 0-6) on 1 or more of the
screening visit days, treatment with an approved dose of an H1-
antihistamine (ASTERIA I and II) or with an H1-antihistamine up
to 4 times the approved dose plus LTRAs or H2-antihistamines, or
all 3 for 3 or more consecutive days immediately before day e14
(GLACIAL), and no missing symptom diary (eDiary) entries in the
7 days before randomization. Exclusion criteria for all 3 studies
included clearly deﬁned inducible trigger for chronic urticaria (eg,
cold, pressure); presence of a disease with symptoms of urticaria or
angioedema; or routine doses (daily or every other day for 5
consecutive days) of systemic steroids, hydroxychloroquine, metho-
trexate, cyclosporine, cyclophosphamide, or intravenous immuno-
globulin within 30 days before day 14, or treatment with
omalizumab in prior year. The individual study publications provide
more detailed discussion of exclusion criteria.9,11
Assessments
Detailed descriptions of the assessments used in the studies have
been published.9-11 Brieﬂy, patients completed a symptom diary
each morning and evening that recorded scores (scale range: 1-3) for
itch severity, the number of hives, and size of largest hive using a
hand-held electronic device. The means of the morning and evening
scores for itch severity and number of hives were summed to derive
the UAS7 (total score range 0-42; higher score reﬂects greater disease
activity). The weekly ISS is the sum of the daily ISS for 7 days (total
score range 0-21; higher score reﬂects greater itch severity). Patients
also recorded the presence of angioedema (yes/no) in the electronic
diary. They completed the DLQI at baseline and weeks 4 and 12
(score range 0-30; higher score represents greater impairment).
Data analyses
For the analyses of efﬁcacy endpoints, data from the placebo,
omalizumab 150-mg, and omalizumab 300-mg treatment arms of
ASTERIA I and II were pooled and analyzed. The 300-mg treatment












Age (y) 41.7 (14.2) 42.1 (13.6) 43.3 (13.4) 44.3 (14.7) 42.7 (13.9)
Female sex, n (%) 107 (67.3) 129 (79.6) 123 (76.9) 55 (66.3) 186 (73.8)
Race, n (%)
White 134 (84.3) 133 (82.1) 142 (88.8) 75 (90.4) 223 (88.5)
Weight (kg) 83.7 (23.2) 82.8 (22.5) 80.9 (19.7) 87.2 (25.2) 82.8 (21.5)
<80 kg, n (%) 76 (47.8) 81 (50.0) 86 (53.8) 40 (48.2) 128 (50.8)
Body mass index (kg/m2) 29.3 (7.0) 29.9 (7.5) 29.2 (6.6) 31.0 (9.6) 29.4 (7.1)
Time since diagnosis of CIU/CSU† (y) 7.1 (10.1) 7.4 (9.0) 6.2 (7.6) 8.8 (11.2) 7.0 (8.8)
Positive CU index test,z n (%) 48 (30.2) 43 (26.7) 39 (24.5) 27 (32.5) 76 (30.4)
No. of previous CIU/CSU
medications, mean (median)
4.7 (4) 4.5 (4.0) 4.4 (4) 6.4 (6) 5.9 (6)
Previous use of systemic steroids, n (%) 68 (42.8) 65 (40.1) 66 (41.3) 44 (53.0) 121 (48.0)
Total IgE levelx (IU/mL), median (range) 80.5 (1-1010) 71.0 (1-5000) 89.0 (1-2330) 71.0 (1-1230) 79.0 (1-3050)
In-clinic UASk 5.3 (0.7) 5.3 (0.7) 5.3 (0.8) 5.2 (0.8) 5.2 (0.8)
UAS7{ 31.1 (6.6) 30.8 (7.1) 30.4 (6.4) 30.2 (6.7) 31.2 (6.6)
Weekly ISS{ 14.2 (3.5) 14.2 (4.0) 13.9 (3.4) 13.8 (3.6) 14.0 (3.6)
13, n (%) 99 (62.3) 100 (61.7) 95 (59.4) 50 (60.2) 154 (61.1)
Weekly number of hives score{ 16.9 (4.3) 16.7 (4.4) 16.5 (4.3) 16.4 (4.6) 17.1 (4.2)
Weekly size of largest hives score{ 15.3 (3.9) 15.2 (4.3) 15.1 (4.0) 15.2 (3.6) 15.1 (4.3)
Overall DLQI score 13.3 (6.3) 13.3 (6.6) 12.9 (6.5) 13.0 (6.9) 13.8 (6.7)
Angioedema present, n (%){ 74 (46.5) 76 (46.9) 66 (41.3) 41 (49.4) 137 (54.4)
CIU/CSU, Chronic idiopathic urticaria/chronic spontaneous urticaria; CU, chronic urticaria; DLQI, Dermatology Life Quality Index; IgE, immunoglobulin E; ISS, itch severity
score; mITT, modiﬁed intention-to-treat; UAS, urticaria activity score; UAS7, urticaria activity score over 7 d.
*Analyses are based on the mITT population. Data are presented as means (standard deviation) unless otherwise stated.
†ASTERIA I/II pooled: placebo, n ¼ 155, omalizumab 150 mg, n ¼ 159, omalizumab 300 mg, n ¼ 157; GLACIAL: placebo, n ¼ 83; omalizumab 300 mg, n ¼ 246.
zASTERIA I/II pooled: omalizumab 150 mg, n ¼ 161 and 300 mg, n ¼ 159; GLACIAL: placebo, n ¼ 83; omalizumab 300 mg ¼ 250.
xASTERIA I/II pooled: placebo, n ¼ 154, omalizumab 150 mg, n ¼ 154, 300 mg, n ¼ 152; GLACIAL: placebo, n ¼ 82; omalizumab 300 mg, n ¼ 244.
kDeﬁned as the largest value from the day 14 screening visit, day 7 screening visit, and day 1 visit.
{Based on data collected in a patient daily diary in the 7 d before the ﬁrst treatment date.
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GLACIAL study. Data from the 75-mg arm of ASTERIA I and II
were not evaluated in this pooled analysis because 75 mg was
considered an ineffective dose in ASTERIA I (did not reach the pri-
mary endpoint) and this dose was not evaluated in the GLACIAL
study. The results for the omalizumab 75-mg dose in patients with
CIU/CSU have been reported separately.9,10 For the primary
endpoint, analysis of covariance models stratiﬁed by baseline weekly
ISS (<13, 13) and baseline weight (<80, 80 kg) were used to
generate the differences between each of the omalizumab groups and
the placebo group in the least-squares means of the change from
baseline in weekly ISS at week 12. Similar models were used for the
other endpoints that measured change from baseline. The modiﬁed
intention-to-treat (mITT) population included all randomized pa-
tients who received at least 1 dose of study drug. Efﬁcacy analyses were
conducted using data from the mITT population, except for the
analysis of proportion of angioedema-free days from week 4 to week
12. For the evaluation of this endpoint, patients who withdrew before
the week 4 visit or who had missing responses for more than 40% of
the daily diary entries between the week 4 study visit and the week 12
study visit were not included. In analyses of endpoints evaluating
change from baseline to week 12, missing data at week 12 were
imputed with the baseline observation carried forward, except for
DLQI, for which no imputation was performed. Safety data in the
form of adverse events (AEs) reported during week 1 to week 12 of
treatment were pooled from all 3 studies. Safety data from the placeboand omalizumab 150-mg and 300-mg arms of each study were
summarized descriptively. Potential anaphylactic events were identi-
ﬁed through an automated search of the AE database using a narrow
search for terms representing core anaphylactic terms and a broad
search that included signs and symptoms of anaphylaxis based on the
Sampson criteria.13 Identiﬁed events with a temporal association with
omalizumab administration were sent for external adjudication (see
the Online Repository available at www.jaci-inpractice.org for mem-
bers of the Anaphylaxis Review Committee).RESULTS
Efficacy
The baseline demographic and disease characteristics for the
ASTERIA I and II pooled populations and the GLACIAL
population were generally similar, except for previous and cur-
rent therapy for CIU/CSU, which were in accordance with the
eligibility criteria in the studies. The median number of previous
medications for CIU/CSU was higher in patients in GLACIAL
than in the ASTERIA I and II pooled population (Table I). The
mean weekly ISS was signiﬁcantly reduced from baseline at week
12 in the pooled ASTERIA I and II omalizumab 150- and 300-
mg treatment arms and in the GLACIAL omalizumab 300-mg
arm (Table II). The magnitude of the reduction in weekly ISS
at week 12 was similar between the omalizumab 300-mg groups
in the ASTERIA I and II pooled and GLACIAL studies






150 mg (n [ 162)
Omalizumab




300 mg (n [ 252)
Primary/key efﬁcacy endpoint
Change from baseline to week 12 in weekly ISS 4.38 (5.44) 7.40 (6.39) 9.58 (5.83) 4.01 (5.87) 8.55 (6.01)
P vs placebo - <.0001 <.0001 - <.0001
Additional endpoints
Change from baseline to week 12 in UAS7 9.17 (11.56) 16.18 (13.17) 21.24 (12.45) 8.50 (11.71) 19.01 (13.15)
P vs placebo - <.0001 <.0001 - <.0001
Change from baseline to week 12 in weekly
no. of hives score
4.79 (6.57) 8.78 (7.23) 11.66 (7.40) 4.49 (6.33) 10.46 (7.74)
P vs placebo <.0001 <.0001 <.0001
Median (95% CI) time to weekly ISS MID
response up to week 12 (wk)†
4.0 (3.0, 5.0) 2.0 (NE, NE) 1.0 (1.0, 2.0) 5.0 (3.0, 7.0) 2.0 (1.0, 2.0)
HR vs placebo (95% CI) - 1.53 (1.19, 1.96) 2.16 (1.68, 2.77) - 1.99 (1.47, 2.68)
P vs placebo .0009 <.0001 <.0001
Patients with weekly ISS MID response, n (%)† 62 (42.1) 1.02 (63.0) 123 (76.9) 33 (39.8) 176 (69.8)
P vs placebo - .0002 <.0001 - <.0001
Change from baseline to week 12 in weekly
size of largest hive score
3.99 (5.48) 7.41 (6.71) 10.38 (6.93) 3.09 (5.46) 8.82 (7.23)
P vs placebo <.0001 <.0001 <.0001
Change from baseline to week 12 in DLQI scorez 6.11 (6.89) 8.15 (6.74) 10.22 (7.01) 5.11 (7.53) 9.69 (6.85)
P vs placebo - .0109 <.0001 - <.0001
Proportion of angioedema-free days from
week 4 to week 12x
88.7 (19.1) 90.6 (19.0) 95.8 (12.9) 88.1 (18.9) 91.0 (21.0)
P vs placebo - .0301 <.0001 - .0006
CI, Conﬁdence interval; DLQI, Dermatology Quality of Life Index; HR, hazard ratio; ISS, itch severity score; MID, minimally important difference; NE, not evaluated; UAS7,
urticaria activity score over 7 d.
*Mean (standard deviation) based on modiﬁed intention-to-treat population unless otherwise noted.
†Minimally important difference response in weekly ISS was deﬁned as 5-point reduction.
zASTERIA I/II pooled: placebo, n ¼ 131, omalizumab 150 mg, n ¼ 133, 300 mg, n ¼ 145; GLACIAL: placebo, n ¼ 64; omalizumab 300 mg, n ¼ 216.
xASTERIA I/II pooled: placebo, n ¼ 136, omalizumab 150 mg, n ¼ 144, 300 mg, n ¼ 148; GLACIAL: placebo, n ¼ 68; omalizumab 300 mg, n ¼ 224.
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group were consistent with the known dose response of omali-
zumab (Table II). The proportions of patients with well-
controlled symptoms (UAS7 6) and with complete symptom
control (UAS7 ¼ 0) were signiﬁcantly greater than placebo in
each of the omalizumab groups and were comparable in the 300-
mg treatment arms of the pooled ASTERIA I and II and
GLACIAL populations (Figure 2). Compared with placebo, the
duration of time to MID response was signiﬁcantly shorter for
patients in the omalizumab groups and a higher proportion of
patients in the omalizumab groups were weekly ISS MID re-
sponders (5-point reduction) at week 12 in both the pooled
ASTERIA I and II and GLACIAL populations (Table II). Sig-
niﬁcant treatment differences for omalizumab compared with
placebo were observed across the other efﬁcacy endpoints, and
the magnitude of the differences was comparable in the
ASTERIA I and II pooled and GLACIAL 300-mg treatment
arms (Table II).
In terms of percentage change from baseline at week 12, the
weekly ISS was reduced from baseline by an additional 38%
and 36% over placebo in patients treated with 300-mg omali-
zumab in the pooled ASTERIA I and II and GLACIAL pop-
ulations, respectively, and by an additional 25% over placebo in
patients treated with 150-mg omalizumab in ASTERIA I and
II (all P <.0001; Figure 3). Similar results were observed forpercentage reductions from baseline in UAS7 and weekly num-
ber of hives score at week 12 compared with placebo (Figure 3).
At week 12, the mean change in DLQI scores had improved
from baseline by an additional 30% over placebo in the
ASTERIA I and II populations and by an additional 50% in
GLACIAL (both P <.0001; Figure 3). Percentage reductions in
the selected endpoints were similar when ASTERIA I and II were
evaluated separately (see Table E1 in this article’s Online Re-
pository at www.jaci-inpractice.org).
Safety
Omalizumab 150 mg and 300 mg were well tolerated as add-
on therapy in patients with CIU/CSU who were symptomatic
despite treatment with approved doses of H1-antihistamines.
Omalizumab 300 mg was also well tolerated in those who were
taking standard combination therapies for CIU/CSU.
Baseline characteristics for the patient safety population were
similar (see Table E2 in this article’s Online Repository at www.
jaci-inpractice.org). Overall, few patients discontinued treatment
(4.0%) or the study (1.1%) because of an AE. The rates of
treatment and study discontinuation as a result of an AE in the
pooled dataset were 3.4% and 1.7% in the omalizumab 150-mg
group, 3.6% and 1.2% in the 300-mg group, and 5.4% and
1.7% in the placebo group. During the treatment period from
week 1 to week 12, the proportions of patients with 1 AE were
*
33.7
FIGURE 2. Proportion of responders by treatment group. *P < .0001. †P ¼ .002. UAS7, urticaria activity score over 7 d. Results for the
GLACIAL study from Kaplan et al.11
J ALLERGY CLIN IMMUNOL PRACT
SEPTEMBER/OCTOBER 2015
748 CASALE ETALsimilar in the omalizumab 150-mg and 300-mg groups, but
higher than in the placebo group (Table III). During the 12-
week treatment period, the rate of serious AEs (SAEs) was low;
the rate of SAEs was higher in the placebo group than in either of
the omalizumab treatment groups (Table III). SAEs reported in
the placebo group included hemorrhoids, hypersensitivity,
pneumonia, radius fracture, type 2 diabetes mellitus, hypergly-
cemia, cervical dysplasia, and chronic obstructive pulmonary
disease. SAEs were hypertension reported in the omalizumab
150-mg group and melena, retroperitoneal infection, pelvic ab-
scess, angioedema, and tonsillectomy in the omalizumab 300-mg
group.
Most AEs were mild or moderate in severity; 6.2% of patients
in the placebo group, 1.7% of patients in the omalizumab 150-
mg group, and 5.3% of patients in the omalizumab 300-mg
group experienced a severe AE (Table III). From week 1 to
week 12 of the treatment period, sinusitis (4.9% vs 2.1%), viral
upper respiratory tract infection (0.5% vs 0%), arthralgia (2.9%
vs 0.4%), headache (6.1% vs 2.9%), and cough (2.2% vs 1.2%)
were more common in the omalizumab 300-mg group compared
with the placebo group. Nasopharyngitis (9.1% vs 7.0%), viral
upper respiratory tract infection (2.3% vs 0%), arthralgia (2.9%
vs 0.4%), and headache (12.0% vs 2.9%) were more common in
the omalizumab 150-mg group than in the placebo group. There
was no evidence of dose-related AEs.
The proﬁle of AEs during the longer 24-week treatment
period in ASTERIA I9 and GLACIAL11 was similar to that
observed for the pooled data during the 12-week treatment
period, which suggested that there were no observable late-onset
events or any change in the rate of AEs with increased duration
of exposure. The AE proﬁle observed in the pooled phase III
studies was consistent with that known for omalizumab in pa-
tients with allergic asthma,14-18 with the exception of AEs spe-
ciﬁc to the respective indications (eg, urticaria, pruritus). There
were no events of anaphylaxis related to omalizumab reported. In
subanalyses, the AE proﬁle was similar regardless of background
therapy for CIU/CSU.Time to loss of response
The median time to loss of response in patients who had
achieved a UAS7 6 (well controlled) at the end of the treatment
period (week 12: ASTERIA I; week 24: ASTERIA I and
GLACIAL) was similar in all 3 studies. Median time to loss of
response for the 150-mg and 300-mg doses of omalizumab was 3
weeks and 5 weeks, respectively, in both ASTERIA I and II. In
GLACIAL, the median time to a loss of response was reported at
7 weeks for omalizumab 300 mg. Placebo patients reported a
median time to loss of response at 7 weeks in ASTERIA I, 6
weeks in ASTERIA II, and 4.5 weeks for placebo-treated pa-
tients; this was most likely a reﬂection of the waxing and waning
of the disease. No rebound effect following omalizumab
discontinuation was noted.DISCUSSION
Using data from the phase III studies for CIU, we sought to
compare the efﬁcacy, safety, and time to loss of response of
omalizumab in patients with different background therapy.
Despite differences in background therapy between studies,
including triple therapy (H1-antihistamines, H2-antagonists, and
LTRAs), we observed similar treatment effect sizes across mul-
tiple endpoints. This suggests that background therapies in pa-
tients with refractory disease do not affect response to
omalizumab (ie, patients with more intense background therapy
respond at the same level as those with less intense background
treatment).
At baseline, mean DLQI scores were higher (ie, worse health-
related quality of life [HRQoL]) than those observed in patients
with atopic dermatitis, moderate to severe psoriasis, or psoriatic
arthritis,19,20 which indicated considerable impact of CIU/CSU
symptoms on HRQoL. Consistent treatment effects for omali-
zumab 300 mg versus placebo were observed across multiple
efﬁcacy endpoints in patients receiving different background
therapies for CIU/CSU. After 12 weeks of treatment










FIGURE 3. Percent reductions in key endpoints from baseline to week 12. *P < .0001. †P ¼ .034. DLQI, Dermatology Life Quality Index;
ISS, itch severity score; UAS7, urticaria activity score over 7 d.
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CASALE ETAL 749well-controlled symptoms (UAS7 6) and more than one third
were completely itch- and hive-free (UAS7 ¼ 0).
The European/World Allergy Organization (EAACI/GA2
LEN/EDF/WAO) published guidelines for the management of
CIU/CSU suggest that omalizumab should be used as the third
line of therapy (ie, on top of increased dosage up to 4-fold of
modern second generation antihistamines) in the algorithm of
treatment of urticaria (strong recommendation/high level evi-
dence).1 However, the US published guidelines for the man-
agement of CIU/CSU suggest that omalizumab should be used
as the fourth step of therapy.21 Yet, there are limited to no robust
clinical data that demonstrate incremental response rates for
therapies other than omalizumab after using step 2 therapies.
Whether or not omalizumab should also be considered as a third-
step treatment in the United States (after up-dosing of second
generation H1-antihistamines) remains to be determined. A
systematic review of omalizumab in patients with CIU deter-
mined that the 300 mg dose has the most compelling data
supporting its use.6 The more recently published omalizumab
phase III results, including this pooled analysis, will likely be of
importance to include in such assessments.
There were few serious AEs and the rate of serious AEs was
lower in the omalizumab 300-mg group than in the placebo
group. With the exception of urticaria-speciﬁc AEs, the most
common AEs were consistent with those known for omalizumab
in allergic asthma with no instances of anaphylaxis. Most AEs
were mild to moderate in severity. Taken together with the ef-
ﬁcacy results, the totality of the data suggests a favorable beneﬁt-
risk proﬁle for omalizumab in the treatment of CIU.The loss of response after discontinuation of therapy was similar
despite the length of treatment received by the patient, which
suggested that disease modiﬁcation does not occur at these treat-
ment durations. Rebound did not occur following omalizumab
discontinuation. The return of symptoms on a consistent basis
highlights the need for more prolonged therapy and a continued
unmet need in this population of patients for disease modiﬁcation.
Treatment with omalizumab offers a fast onset of relief from
symptoms for many patients with difﬁcult-to-manage symptoms,
yet the nature of the disease requires treatments that can reduce
symptomatology on a chronic basis. Although efﬁcacy over a 6-
month treatment period has been demonstrated,9,11 further
studies that evaluate long-term treatment with omalizumab in
CIU/CSU are needed to examine beneﬁts with chronic therapy.
On a practical level, the population of patients in the
GLACIAL study, in which patients were taking multiple
concomitant therapies for CIU/CSU, may be more reﬂective of
patients with H1-antihistamine-refractory CIU/CSU encountered
in clinical practice. These patients with refractory symptoms
continued the background therapies once they entered the trial
and demonstrated similar responses to omalizumab as patients
receiving less intense background treatment (ie, approved doses of
H1-antihistamines) indicating that the response to omalizumab is
not appreciably inﬂuenced by background therapies.
Because the placebo-controlled period in the ASTERIA II
study was 12 weeks, the current pooled analyses were limited to
evaluating changes up to week 12. However, 2 of the 3 studies,
ASTERIA I9 and GLACIAL,11 also provide safety and efﬁcacy
information for the longer treatment period of 24 weeks.
TABLE III. Patients with treatment-emergent adverse events
during weeks 1 to 12 of treatment in ASTERIA I, ASTERIA II,
and GLACIAL combined









Any AE 103 (42.6) 96 (54.9) 210 (51.0)
Serious AEs 8 (3.3) 1 (0.6) 5 (1.2)
AEs by severity
Mild 41 (16.9) 50 (28.6) 94 (22.8)
Moderate 47 (19.4) 42 (24.0) 91 (22.1)
Severe 15 (6.2) 3 (1.7) 22 (5.3)
AEs with incidence 3%
Infections and infestations 44 (18.2) 40 (22.9) 94 (22.8)
Upper respiratory
tract infections
30 (12.4) 23 (13.1) 63 (15.3)
Nasopharyngitis 17 (7.0) 16 (9.1) 27 (6.6)
Sinusitis 5 (2.1) 2 (1.1) 20 (4.9)
Upper respiratory
tract infection
5 (2.1) 2 (1.1) 14 (3.4)
Nervous system disorders 14 (5.8) 26 (14.9) 42 (10.2)
Headache 7 (2.9) 21 (12.0) 25 (6.1)
Respiratory, thoracic, and
mediastinal disorders
11 (4.5) 9 (5.1) 29 (7.0)
Coughing and associated
symptoms
3 (1.2) 2 (1.1) 12 (2.9)
Cough 3 (1.2) 2 (1.1) 9 (2.2)
Skin and subcutaneous
tissue disorders
23 (9.5) 12 (6.9) 45 (10.9)
Urticarias 12 (5.0) 5 (2.9) 16 (3.9)
Idiopathic urticaria 6 (2.5) 1 (0.6) 9 (2.2)
AE, Adverse event.
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750 CASALE ETALAdditional studies in real-world populations will provide addi-
tional information on the efﬁcacy and safety of omalizumab. One
limitation of the UAS7 is that noneurticaria-related itch is
captured and this may result in underestimation of the rate of
complete response (ie, UAS7 ¼ 0) to omalizumab. The analyses
were based on clinical studies with strict eligibility criteria, and,
thus, the results may not be generalizable to all patients
encountered in clinical practice. The indirect comparisons across
different studies and the post hoc nature of the analyses are further
limitations of note.
In summary, the ﬁndings from this post hoc analysis indicate that
omalizumab 300 mg had similar efﬁcacy in CIU/CSU patients
regardless of the background therapy for urticaria used in the trials,
and the safety proﬁle in CIU was generally similar to that in allergic
asthma. There was no evidence of dose-related safety issues.Acknowledgments
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TABLE E1. Percentage reductions from baseline in key endpoints at week 12 in ASTERIA I and ASTERIA II
Endpoint




150 mg (n [ 80)
Omalizumab




150 mg (n [ 82)
Omalizumab
300 mg (n [ 79)
Weekly ISS* 25.5% (38.1) 47.7% (42.5) 66.6% (36.3) 36.2% (38.9) 56.0% (43.2) 70.6% (41.3)
Difference vs placebo (95% CI)† - 21.8% (9.7, 34.0)z 40.5% (28.4, 52.6)z - 19.9% (6.6, 33.2)x 34.5% (21.1, 48.0)z
UAS7* 25.5% (38.5) 48.8% (41.4) 67.0% (36.6) 33.7% (39.2) 56.6% (40.1) 72.6% (40.6)
Difference vs placebo (95% CI)† - 23.2% (11.1. 35.2)x 40.8% (28.7, 52.9)z - 23.0% (10.4, 35.6)x 38.7% (25.9, 51.5)z
Weekly no. of hives score* 25.0% (41.3) 50.2% (41.7) 67.0% (39.2) 31.3% (42.8) 57.3% (40.2) 73.8% (43.3)
Difference vs placebo (95% CI)† - 24.8% (12.2, 37.4)z 41.3% (28.7, 54.0)z - 26.3% (13.2, 39.4)z 42.1% (28.8, 55.3)z
DLQI score*,k 47.2% (41.1) 50.9% (72.5) 73.6% (40.6) 44.0% (54.1) 65.5% (36.4) 77.6% (34.0)
Difference vs placebo (95% CI)† - 2.9% (15.3, 21.1){ 26.2% (8.6, 43.8)x - 22.1% (6.2, 37.9)x 33.3% (17.6, 48.9)z
CI, Conﬁdence interval; DLQI, Dermatology Life Quality Index; ISS, itch severity score; UAS7, urticaria activity score over 7 days.
*Mean (SD) percentage reduction from baseline to week 12.
†Treatment difference in least-squares means relative to placebo.
zP <.0001.
xP <.05.
kNumber of patients: ASTERIA I, placebo, n ¼ 62, omalizumab 150 mg, n ¼ 63 and 300 mg, n ¼ 72; ASTERIA II, placebo, n ¼ 69, omalizumab 150 mg, n ¼ 70 and
omalizumab 300 mg, n ¼ 73.
{Not signiﬁcant.
TABLE E2. Patient characteristics at baseline (safety data)*





Age (y) 42.6 (14.4) 42.9 (13.7)
Female sex, n (%) 162 (66.9) 309 (75.0)
Race, n (%)
White 209 (86.4) 365 (88.6)
Weight (kg) 84.9 (23.9) 82.1 (20.9)
<80 kg, n (%) 116 (47.9) 214 (51.9)
Body mass index (kg/m2) 29.9 (8.0) 29.3 (6.9)
Time since diagnosis of
CIU/CSU (y)†
7.7 (10.5) 6.7 (8.3)
Positive CU Index test, n (%) 75 (31.0) 115 (28.1)
Number of previous CIU/CSU
medications, mean (median)
5.3 (3.0) 5.3 (2.6)
Previous use of systemic
steroids, n (%)
112 (46.3) 187 (45.4)
Total IgE level (IU/mL),
median (range)z
80.0 (1-1230) 79.0 (1-3050)
In-clinic UASx 5.3 (0.7) 5.2 (0.8)
UAS7k 30.8 (6.6) 30.9 (6.5)
Weekly ISSk 14.1 (3.5) 14.0 (3.5)
13, n (%) 149 (61.6) 249 (60.4)
Weekly number of hives scorek 16.7 (4.4) 16.9 (4.2)
Angioedema present, n (%)k 115 (47.5) 203 (49.3)
CIU/CSU, Chronic idiopathic urticaria/chronic spontaneous urticaria; CU, chronic
urticaria; ISS, itch severity score; UAS, urticaria activity score; UAS7, urticaria
activity score over 7 d.
*Data are presented as means (standard deviation) unless otherwise stated.
†Number of patients: placebo, n ¼ 238, omalizumab 300 mg, n ¼ 403.
zPlacebo, n ¼ 236; omalizumab 300 mg, n ¼ 396.
xDeﬁned as the largest value from the day 14 screening visit, day 7 screening
visit, and day 1 visit.
kBased on data collected in a patient daily diary in the 7 d before the ﬁrst treatment
date.
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